Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities

Caiguo Zhang1, Fan Zhang2

1 Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, CO 80045, USA
2 Orthopedics Department, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
Correspondence: caiguo.zhang@ucdenver.edu (C. Zhang)
Received October 16, 2014 Accepted November 4, 2014

ABSTRACT
Excess iron is tightly associated with tumorigenesis in multiple human cancer types through a variety of mechanisms including catalyzing the formation of mutagenic hydroxyl radicals, regulating DNA replication, repair and cell cycle progression, affecting signal transduction in cancer cells, and acting as an essential nutrient for proliferating tumor cells. Thus, multiple therapeutic strategies based on iron deprivation have been developed in cancer therapy. During the past few years, our understanding of genetic association and molecular mechanisms between iron and tumorigenesis has expanded enormously. In this review, we briefly summarize iron homeostasis in mammals, and discuss recent progresses in understanding the aberrant iron metabolism in numerous cancer types, with a focus on studies revealing altered signal transduction in cancer cells.

KEYWORDS Iron tumorigenesis, p53, Wnt, DNA repair, cell cycle

INTRODUCTION: OVERVIEW OF IRON AND CANCER
Iron serves important functions for mammalian cells as it is involved in cell proliferation, metabolism and growth (Torti and Torti, 2013). These processes are controlled by a variety of iron- and heme-containing proteins, including enzymes involved in DNA stability and cell cycle progression, mitochondrial enzymes involved in respiratory complexes, and detoxifying enzymes such as peroxidase and catalase (Torti and Torti, 2013; Zhang, 2014). Within the human body, iron biologically exists in two oxidation states: ferrous iron (Fe2+) and ferric iron (Fe3+) (Pantopoulos et al., 2012; Rouault, 2003). Iron has the property of gaining and losing electrons, which enables it to participate in Fenton reaction (Pantopoulos et al., 2012; Torti and Torti, 2013), in which Fe2+ donates an electron in a reaction with hydrogen peroxide (H2O2) to produce the hydroxyl radical (HO) (Thomas et al., 2009), a reactive oxygen species (ROS). Human body needs to maintain systemic and cellular iron homeostasis by regulating iron acquisition, storage and efflux (Zhang, 2014). Iron homeostasis is not only required for iron-containing protein functions, but also critical for signal transduction and cellular microenvironment (Xiong et al., 2014). The elevated iron may result in the generation of ROS, which can damage lipids, proteins and DNA, eventually leading to tumorigenesis (Orrenius et al., 2011; Romero et al., 2014). It has been reported that numerous types of cancers are implicated by iron, such as lung cancer, breast cancer, prostate cancer, colorectal cancer, hepatocellular cancer, pancreatic cancer and hematological malignancies (Fig. 1) (Torti and Torti, 2013). On the other hand, iron deficiency caused anemia is one of the major public health problems, particularly in children and pregnant women (Denic and Agarwal, 2007; Miller, 2013). The recent studies also indicate that many patients with cancer have anemia (Munoz et al., 2014), but the cause is still to be determined.

Previous studies suggest that iron may function in tumour initiation, tumour growth, tumour microenvironment and metastasis (Mantovani et al., 2008; Sica et al., 2008). In cancer cells, pathways involved in iron acquisition, trafficking, storage and regulation are all perturbed, suggesting that iron metabolism is important for tumour cell survival (Torti and Torti, 2013). Additionally, iron can also contribute to DNA replication and repair processes, as well as cell cycle control...
in cancer cells (Torti and Torti, 2013; Zhang, 2014). Signaling through p53, Wnt, hypoxia-inducible factor (HIF), DNA replication, repair and cell cycle progression pathways may associate with altered iron metabolism in cancer (Torti and Torti, 2013). Thus, decreasing cellular iron levels, targeting iron metabolic pathways and iron-containing proteins may provide new tools for cancer therapy.

**IRON METABOLISM IN MAMMALS**

Mammalian organisms have evolved sophisticated mechanisms to regulate systemic and cellular iron balance (Andrews and Schmidt, 2007; Pantopoulos et al., 2012).

**Systemic iron metabolism**

Generally, systemic iron regulatory processes include several critical steps: (1) duodenal enterocytes acquire dietary iron via divalent metal transporter 1 (DMT1), also known as solute carrier family 11 member 2 (SLC11A2), natural resistance-associated macrophage protein 2 (NRAMP2), or divalent cation transporter (DCT1) (Pantopoulos et al., 2012). DMT1 localizes on the apical surface and functions dependently on the reduction of Fe$^{3+}$ to Fe$^{2+}$ by duodenal cytochrome b (DcytB) (Pantopoulos et al., 2012); (2) splenic reticuloendothelial macrophages are responsible for iron recycling from senescent red blood cells (Pantopoulos et al., 2012); (3) iron exporter ferroportin (Fpn) releases iron oxidized prior by hephaestin from Fe$^{2+}$ to Fe$^{3+}$ (Pantopoulos et al., 2012); (4) transferrin (Tf) located on plasma membrane acquires and delivers iron in the body (Pantopoulos et al., 2012); and (5) hepatic hormone hepcidin controls systemic iron trafficking and iron efflux from cells by regulating Fpn stability (Pantopoulos et al., 2012; Zhang, 2014).

**Cellular iron metabolism**

Cellular iron homeostasis is controlled by iron uptake at the plasma membrane, eliciting balanced iron distributions among cellular compartments and iron export (Valerio, 2007; Zhang, 2014). Briefly, most mammalian cells acquire iron via Tf to form holo-Tf (Anderson and Vulpe, 2009; Dunn et al., 2007), which further binds to transferrin receptor 1 (TfR1) to form holo-Tf-TfR1 complex on the iron-consuming cell membrane (Zhang, 2014). This complex is subsequently internalized by receptor-mediated endocytosis (Lill et al., 2012) and acidified in the endosome, facilitating the release of Fe$^{3+}$ from holo-Tf (Zhao et al., 2010). The six-transmembrane epithelial antigen of the prostate 3 (Steap3) reduces Fe$^{3+}$ to Fe$^{2+}$, followed by transporting Fe$^{2+}$ into the cytoplasm by DMT1 or transient receptor potential protein potential (TRPML1) (Zhang et al., 2012). Later, the holo-Tf-TfR1 complex disassembles and apo-Tf recycles back to the cell membrane to repeat another cycle (Pantopoulos et al., 2012). Thereafter, the newly acquired iron stores into the cytosolic “labile iron pool” (Gkouvatos et al., 2012; Pantopoulos et al., 2012). The excess cellular iron is either stored in ferritin or exported via Fpn (Pantopoulos et al., 2012) (Fig. 2). Moreover, two iron regulatory proteins, namely, IRP1 and IRP2, can post-transcriptionally regulate cellular iron homeostasis (Zhang, 2014). In low iron condition, IRP1 and IRP2 proteins specifically bind to iron-responsive elements (IRE) in 3′- or 5′-UTR of the mRNA transcripts in TfR1, ferritin heavy (H) chain, ferritin light (L) chain, or DMT1 (Zhang, 2014). The IRE-IRP system functions importantly in the control of mammalian iron homeostasis (Pantopoulos et al., 2012). Consequently, these iron regulatory proteins are protected from degradation or their translations are inhibited (Anderson and Vulpe, 2009; Dunn et al., 2007; Kaplan and Kaplan, 2009; Muckenthaler et al., 2008).

**IRON IS IMPLICATED IN A VARIETY OF CANCER TYPES**

Multiple cancer types have been widely reported to exhibit abnormal iron contents or deficiency in iron uptake, utilization and storage (Fig. 3). These cancers mainly include lung cancer, breast cancer, prostate cancer, colorectal cancer, hepatocellular cancer, pancreatic cancer, haematological cancers, renal cell carcinoma and melanoma (Fig. 1) (Torti and Torti, 2013).

**Lung cancer**

Lung cancers are generally categorized as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (Vescio et al., 1990). During the past few years, hepcidin and...
several iron metabolism related proteins have been demonstrated to associate with lung cancer genesis and tumor cell proliferation (Xiong et al., 2014). Hepcidin expression is increased in tumor tissue and serum of NSCLC patients, and the increased serum hepcidin level is associated with lymph node metastasis and tumor clinical stage of NSCLC (Xiong et al., 2014). Iron related proteins, such as TfR1, H and L subunits of ferritin protein, also exhibit increased levels in lung cancer. In H1299 lung cancer cells, the induction of p53 decreases iron regulatory protein binding, leading to an increase in both H and L subunits of ferritin protein, but a decline of TfR1 level (Zhang et al., 2008). However, some studies reported elevated expression of TfR1 in NSCLC patients (Kukulj et al., 2010; Xiong et al., 2014). The elevated serum ferritin levels were observed in NSCLC and SCLC patients (Aleman et al., 2002; Kukulj et al., 2010; Yildirim et al., 2007), and in patients with cancer during radiotherapy (Koc et al., 2003). However, the expression of FPN in lung cancer cells has not been reported.

IRP1 is responsible for cytosolic iron concentrations and can post-transcriptionally regulate the expression of iron metabolism genes to maintain cellular iron homeostasis (Rouault, 2006). In cells with iron deficiency, IRP1 can bind to IRE element of ferritin mRNA, enhancing iron uptake and decreasing iron sequestration (Rouault, 2006). The tetracycline-inducible overexpression of IRP1 or IRP1C437S mutant results in misregulation of iron metabolism, highly active in IRE-binding and increased TfR1 levels in human H1299 lung cancer cells (Wang and Pantopoulos, 2002), but not altering the growth properties of the H1299 cells in vitro (Wang and Pantopoulos, 2002). However, overexpression of IRP1 or IRP1C437S dramatically suppresses the growth of tumor xenografts in nude mice (Chen et al., 2007), providing a direct regulatory link between the IRE/IRP system and cancer. In A549 lung cancer cells, IRP2 can regulate the expression of TfR1 and ferritin by changing its own gene expression, and thereby regulating iron metabolism (Cheng et al., 2014). Moreover, exhaled ferritin and superoxide dismutase (SOD)
have recently been recognized to play a role in lung cancerogenesis and patients’ survival (Carpagnano et al., 2012), implying the possibility of using them as an outcome predictor of lung cancer.

Lipocalin-2 (LCN2), which is a member of the lipocalin family and functions to ligate ferric siderophore-like molecules, is involved in various cancers including lung cancer (Shiiba et al., 2013), breast cancer (Yang et al., 2013), ovarian cancer (Cho and Kim, 2009), colon cancer and pancreatic cancer (Mannelqvist et al., 2012). The elevated levels of LCN2 tightly associate with the malignance and metastasis of cancer cells (Leng et al., 2009; Yang et al., 2009). In lung cancer, LCN2 protein level increases significantly after X-ray irradiation (Shiiba et al., 2013), suggesting that overexpression of LCN2 might contribute to radiation resistance in cancer cells (Shiiba et al., 2013).

Breast cancer

Iron is strongly correlative to the risk of breast cancer through many aspects such as interaction with estrogen, disruption of lactoferrin, genetic variability in iron-related oxidative stress pathways, and abnormal expression of iron uptake or export genes (Torti and Torti, 2013).

The majority of breast cancers rely on supplies of estrogen to grow (Oh, 2002). Studies have revealed that estrogen contributes to breast cancer in multifactorial ways, and iron is suggested to interact with estrogen in two different ways (Torti and Torti, 2013). Generally, low level of iron may stimulate HIF1α activation and consequently promote angiogenesis, whereas high level of iron may increase oxidative stress (Torti and Torti, 2013). Recently, estrogen has been considered to contribute to iron homeostasis by regulating hepatic hepcidin expression directly through a functional estrogen response element (ERE) in the promoter region of hepcidin gene (Hou et al., 2012).

A unique correlation between iron and breast cancer is mediated by lactoferrin (Torti and Torti, 2013). Lactoferrin is a member of transferrin family and binds two ferric ions with high affinity (Torti and Torti, 2013; Ward et al., 2003). In human breast cancer cells, the exogenous lactoferrin, or adenovirus-mediated expression of lactoferrin can greatly inhibit cell proliferation (Duarte et al., 2011; Torti and Torti, 2013). In mice bearing EMT6 breast cancer, the injection of recombinant adenovirus containing lactoferrin can induce apoptosis and inhibit tumor growth (Wang et al., 2011), suggesting that lactoferrin has potential benefit in treating some breast cancers.

Several enzymes play critical roles in the formation and reduction of iron-generated ROS, including NAD(P)H:quinone oxidoreductase 1 (NQO1), nitric oxide (NO) synthase (NOS3) and heme oxygenase (HO) (Hong et al., 2007). NQO1 is important for breast carcinogenesis as it functions in the reduction of endogenous catechol estrogens (Hong et al., 2007). In animals, the suppression of NQO1 increases estradiol-dependent tumor formation (Hong et al., 2007; Wyllie and Liehr, 1997). In mouse, the expression of NQO1 is regulated by nuclear factor erythroid 2 related factor 2.
(Nrf2) through consensus regulatory sequence known as the antioxidant response element (ARE) (Hong et al., 2007; Lin et al., 2011). Interestingly, Nrf2 can induce ferritin-H and ferritin-L gene expressions, leading to elevated cellular iron (Hong et al., 2007; Iwasaki et al., 2013). NOS3 generally functions to generate low levels of short-lived nitric oxide (NO) by converting L-arginine to citrulline in endothelial tissue (Hong et al., 2007). At low levels, NO acts as an antioxidant by scavenging ROS and can bind to iron to reduce redox cycling (Trachootham et al., 2008). The increased expression of NOS3 has been detected in breast cancer, which is positively associated with estrogen and progesterone receptor status and negatively involved in histologic grade and lymph node status (Martin et al., 2000; Vakkala et al., 2000). NO also exhibits correlation with iron-related carcinogenesis as it catalyzes the rate-limiting step in heme degradation and provides cellular protection against oxidative stresses (Choi and Alam, 1996; Stocker, 1990).

The abnormal expression of iron homeostasis related genes are also widely examined in breast cancers. In human breast cancer MCF-7 cells, the expression of iron transporter genes including Tfr1, DMT1 and FPN is altered (Jiang et al., 2010). Compared to normal breast cells, the expression of iron importer genes is increased, whereas the expression of FPN is decreased in breast cancer cells to satisfy their increased demands for iron (Jiang et al., 2010). Interestingly, perturbations in ferritin levels are associated with breast cancer progression toward a more advanced malignant phenotype (Shpyleva et al., 2011). For instance, in human breast cancer cell lines with an epithelial phenotype, such as MCF-7, MDA-MB-361, T-47D and HCC70 cells, the expression of ferritin-H, ferritin-L, Tf, TIR1, IRP1 and IRP2 is decreased (Shpyleva et al., 2011). In contrast, the expression of these genes is commonly elevated in cells with an aggressive mesenchymal phenotype, such as Hs-578T, BT-549 and MDA-MB-231 cells (Shpyleva et al., 2011).

Additionally, LCN2 is a novel regulator of angiogenesis in human breast cancer (Yang et al., 2013). LCN2 functions to protect matrix metalloproteinase-9 (MMP-9) against degradation, which further enhances its enzymatic activity and facilitates angiogenesis and tumor growth (Fernandez et al., 2005). Overexpression of LCN2 in MCF7 breast cancer cells increases the expression of vascular endothelial growth factor (VEGF), a key angiogenic activator (Yang et al., 2013). The LCN2-induced VEGF is mediated through HIF1α and that LCN2 regulates HIF1α through extracellular signal-regulated kinase (Erk) (Yang et al., 2013). However, some studies reported that inhibition of LCN2 results in breast tumorigenesis in two different mouse models (Berger et al., 2010; Leng et al., 2011).

Prostate cancer

Prostate cancer is one of the most commonly diagnosed malignancies in men (Al Robaian et al., 2014). Iron also exhibits relevance to prostate cancer, including FPN level reduction (Chen et al., 2014), redox-sensitive transcription factor (NF-κB) activation (Ornstein and Zacharski, 2007), the HIF1α-dependent pathway activation (Tsui et al., 2013), the association between heme iron intake and prostate cancer risk (Jakszyn et al., 2012), and high level of β2-microglobulin (β2-M) in patients with prostate cancer (Josson et al., 2013).

In prostate tumors, the Fpn protein level is significantly reduced by comparison with adjacent tissues, indicating a crucial role of Fpn in prostate tumor growth through controlling iron concentration (Chen et al., 2014). Conversely, inhibition of myeloid zinc-finger 1 (MZF-1) expression, an oncogene or a tumor suppressor, can lead to decreased Fpn level, enhancing tumor cell growth (Chen et al., 2014).

Treatment of the human prostate cancer cell line PC-3 with iron in the form of ferric nitrotriocetate (FeNTA), but in the absence of added transferrin, results in stimulation of intracellular reactive oxygen intermediates (ROI) production, NF-κB activation and increasing urokinase-type plasminogen activator (uPA) expression (Ornstein and Zacharski, 2007). These results imply that non-transferrin-bound iron (NTBI) may indirectly promote prostate cancer growth and metastasis (Ornstein and Zacharski, 2007). In PC-3 and LNCaP human prostate carcinoma cells, hypoxia dysregulates the expressions of lactate dehydrogenase A (LDHA), fatty acid synthase (FASN) and mitochondrial aconitate (mACON) genes (Tsui et al., 2013). In which, the hypoxia-induced mACON gene expression is via the HIF1α-dependent and iron-dependent pathways (Tsui et al., 2013).

Heme iron can promote endogenous production of NOCs (nitrosochromes) and catalyze free radical formation, leading to oxidative cell damage (Jakszyn et al., 2012). The endogenous and exogenous dietary nitrosamines and heme iron intake have potential effect on prostate cancer risk (Jakszyn et al., 2012). Prostate cancer patients with bone metastasis exhibit elevated expression of β2-microglobulin (β2-M), which is a cell membrane protein (Josson et al., 2013). Previous studies have demonstrated that β2-M interacts with hemochromatosis protein (HFE), preventing excessive iron uptake (Josson et al., 2013). The β2-M/HFE complex is required for cancer development and bone metastasis (Josson et al., 2013). Genetic deletion of β2-M or HFE in prostate cancer cells exhibits sensitivity to radiation in vitro and in vivo (Josson et al., 2013).

Colorectal cancer

Studies have demonstrated that iron confers an increased risk for colorectal cancer (CRC). Commonly, increased cellular iron exposure is associated with CRC risk (Pusatiociglu et al., 2014). Heparin, a peptide hormone synthesized mainly in the liver, functions to inhibit iron transport by binding to Fpn (Rossi, 2005). Inappropriately elevated serum hepcidin may reduce duodenal iron absorption, which further increases colonic adenocarcinoma iron exposure in CRC patients (Pusatiociglu et al., 2014). Hereditary hemochromatosis, a genetic disorder of iron overload, generally
Iron homeostasis and cancer

Hepatocellular cancer

The liver is the most frequently affected organ by iron overload because iron is mainly stored in hepatocytes (MacKenzie et al., 2008). Hepatocellular carcinoma (HCC) commonly develops in patients with underlying hereditary hemochromatosis (HH) (Tan et al., 2009). Patients with HCC generally contain elevated iron in their livers, indicating the critical role of iron in stimulation of carcinogenesis (Kowdley, 2004). The wild-type HFE protein can form a complex with TfR, and two HFE mutations (C282T and H63A), and it also has been found to increase the affinity to the TfR (Beckman et al., 2000).

By using immunohistochemistry, the expression of TfR1 and TfR2 is significantly higher in human HCC tissues than in adjacent non-tumor tissues (Sakurai et al., 2014), suggesting that TfR1 and TfR2 are expressed in response to iron deficiency during liver carcinogenesis (Sakurai et al., 2014). Interestingly, in tumors tissues from 24 HCC patients with chronic HBV infection, iron staining assay result by Perls’ Prussian blue was negative, whereas excess iron deposits were present in 17 of the 24 adjacent non-tumorous liver tissues (Tan et al., 2009). The expression of iron-regulatory genes, including hepcidin, TfR2, Tf and IRP1 were significantly down-regulated in the tumorous tissues in comparison to the adjacent non-tumorous liver tissues (Tan et al., 2009). The proteomic and genomic evidences indicated that ferritin-L was suppressed in HCC (Park et al., 2002). The suppressed level of ferritin-L in HCC may be resulted from modification of IRPs, which may tightly bind to the IRE element of a target gene, thereby blocking de novo translation of ferritin-L (Park et al., 2002).

Pancreatic cancer

Pancreatic cancer is one of the most fatal cancers in adult men and women (Bracci, 2012). Obesity is a modifiable risk factors associated with increased risk of pancreatic cancer (Bracci, 2012). Evidence suggests that obesity is associated with higher hemoglobin and ferritin concentrations (Hama-lainen et al., 2012). Ferritin is detected at higher levels in the sera of many patients with pancreatic cancer (Kalousova et al., 2012). Additionally, labile iron has been implicated in both the pathogenesis and treatment of pancreatic cancer (Moser et al., 2013). In human pancreatic cancer cell line MIA PaCa-2, pharmacological ascorbate and irradiation have been shown to increase the labile iron in tumor homogenates (Moser et al., 2013). Heme-iron is associated with increased pancreatic cancer risk in female smokers (Molina-Montes et al., 2012).

An elevated expression of LCN2 has been observed in pancreatic cancer (Leung et al., 2012). In two pancreatic ductal adenocarcinoma cell lines (BxPC3 and HPAF-II), the downregulation of LCN2 significantly reduces attachment, invasion and tumour growth in vivo, but not proliferation or motility (Leung et al., 2012). In contrast, the overexpression of LCN2 in PANC1 cells significantly increases invasion, attachment and tumour growth (Leung et al., 2012). LCN2 promotes the expression of VEGF and HIF1α, which contributes to the enhanced vascularity (Leung et al., 2012). These results indicate that LCN2 is critical for the malignant progression of pancreatic ductal carcinoma.

Haematological malignancies

Haematological cancers include various types of blood cancers and related diseases such as acute and chronic leukaemias, myeloproliferative disorders, myelodysplastic syndromes and aplastic anemia (Koreth and Antin, 2010). Haematologic disorders commonly associate with iron overload due to increased iron absorption and hepcidin suppression (Koreth and Antin, 2010).

Patients with multiple myeloma (MM) have increased serum hepcidin, which inversely correlates with hemoglobin, suggesting that hepcidin contributes to MM-related anemia (Maes et al., 2010). Further studies revealed that hepcidin is induced by increased bone morphogenetic protein 2 (BMP2) (Maes et al., 2010). Hepcidin is upregulated by interleukin-6 (IL-6) in Hodgkin’s lymphoma (HL) patients in comparison to controls (Hohaus et al., 2010). Elevated levels of hepcidin in
Iron and p53

Iron status influences p53 activity and antioxidant response by modulating the expression of MDM2 (mouse double minute gene 2) (Dongiovanni et al., 2010). In mouse hepatocytes and rat liver, iron status has been identified to regulate MDM2, which is associated with specific changes in p53 expression (Dongiovanni et al., 2010). MDM2 functions as a predominant negative regulator of p53, and it controls p53 activity and degradation through ubiquitination (Dongiovanni et al., 2010). Further, iron dependent regulation of MDM2/p53 has been confirmed in human monocytes (Dongiovanni et al., 2010). In which, the manipulation of iron pool leads to modulation of p53 target genes involved in the antioxidant response and apoptosis (Dongiovanni et al., 2010). Iron status influences p53 ubiquitination and degradation rate, and the MDM2 inhibitor nutlin increases p53 levels in iron-depleted cells (Dongiovanni et al., 2010).

Recently, iron metabolism has been revealed to regulate p53 signaling pathway through direct heme-p53 interaction and modulation of p53 localization, stability and function (Shen et al., 2014). Iron can directly affect the expression of p53, which is downregulated during iron excess (Shen et al., 2014). Iron polyporphyrin heme directly binds to p53 protein via the C-terminal CP motif (CACP) (Shen et al., 2014), which is a highly conserved DNA-binding domain (DBD) in eukaryotic p53 proteins (Shen et al., 2014). The binding leads to disruption of p53-DNA interactions, triggering both nuclear export and cytosolic degradation of p53 (Shen et al., 2014).

Iron and Wnt pathways

There are three well-characterized Wnt signaling pathways, including Wnt/β-catenin pathway, noncanonical planar cell polarity (PCP) pathway and noncanonical Wnt/calcium pathway (von Maltzahn et al., 2012). Excessive signaling from the Wnt pathways has been implicated in the development of numerous types of cancers (MacDonald et al., 2009; von Maltzahn et al., 2012). Interestingly, previous studies have revealed a critical requirement of iron in Wnt signaling, and iron chelation serves as an effective mechanism to inhibit Wnt signaling in humans (Song et al., 2011). A series of acyl hydrazones can bind iron in vitro and in intact cells, and the chelating activity is required for abrogating Wnt signaling and blocking the growth of colorectal cancer cell lines with constitutive Wnt signaling (Song et al., 2011). In addition, multiple iron chelators, including desferrioxamine (DFO), deferasirox and ciclopirox olamine, function similarly to inhibit Wnt signaling and cell growth (Song et al., 2011). In an iron-induced mouse model of kidney cancer, an aberrant Wnt signalling was also examined (Torti and Torti, 2013). A soluble iron salt, namely, ferric nitrolotriacetate (FeNTA), can induce nephrotoxicity and kidney cancer in rats and mice models, suggesting that the activation of Wnt signaling may be a common pathway through which iron contributes to malignant progression (Torti and Torti, 2013).

Clearly, iron has important effects on Wnt signaling pathway, and iron mainly contributes to Wnt signaling pathway through the following two aspects: (1) it augments Wnt signalling in cells with aberrant APC or β-catenin, and (2) it downregulates E-cadherin which is essential for the induction and maintenance of polarized and differentiated epithelia in an APC-independent manner (Torti and Torti, 2013). These effects of iron on Wnt signalling may provide insight into the mechanism of iron exacerbating intestinal tumorigenesis, particularly in an APC mutation background (Torti and Torti, 2013).
Iron and HIF pathways

Iron levels can also regulate hypoxia-inducible factor-α (HIFα) proteins, which are transcription factor subunits that are critical for the regulation of hypoxia response (Torti and Torti, 2013). There are three HIFα family members: HIF1α, HIF2α and HIF3α (Peyssonnaux et al., 2007). These subunits can form heterodimers with HIF1β (also known as ARNT), respectively, to function as the HIF transcription factors (Keith et al., 2012), which transcriptionally induce numerous genes responded to hypoxia, including vascular endothelial growth factor A (VEGFA), glucose transporter 1 (GLUT1; also known as SLC2A1), erythropoietin (EPO) and survivin (also known as BIRC5) (Torti and Torti, 2013). These HIFα subunits are posttranslationally regulated by iron-dependent prolyl-hydroxylases (PHD proteins) (Hewitson et al., 2003; Torti and Torti, 2013).

HIF protein activities are induced in many types of tumours, which are generally associated with tumour cell growth and progression (Torti and Torti, 2013). In cancer cells, HIF can induce the expression of a variety of iron metabolism genes, contributing to iron accumulation in cancer cells. For instance, HIF1α induces TIR1 expression, resulting in increasing iron uptake (Lok and Ponka, 1999; Tacchini et al., 1999). HIF1α induces the expression of ceruloplasmin, which is a ferroxidase enzyme to oxidize iron, facilitating the loading of iron onto Tf (Mukhopadhyay et al., 2000). Moreover, HIF1α also induces HO1 expression, leading to the degradation of heme into biliverdin, carbon monoxide and iron; as a result, which enables iron to be recycled (Lee et al., 1997). Additionally, HIF2α induces the expression of FPN, DMT1 and DCYTB in enterocytes to promote systemic iron uptake (Peyssonnaux et al., 2007; Torti and Torti, 2013).

Iron, DNA replication, repair and cell cycle progression

Defects in genes required for DNA replication and repair always cause genetic instability and are associated with multiple human cancer types (Preston et al., 2010). Interestingly, a variety of iron-containing proteins are involved in DNA replication and repair processes, such as DNA polymerases, DNA helicases, and the small subunit of ribonucleotide reductase (RNR) (Zhang, 2014). The eukaryotic DNA synthesis is generally performed via three conserved polymerases: Pol α, Pol δ and Pol ε (Miyabe et al., 2011). All of these DNA polymerases contain a Fe-S cluster in their active holoproteins (Zhang, 2014). DNA helicase and helicase-nuclease enzymes, including Xeroderma pigmentosum group D-complementing protein (XPD; also known as ERCC2), Fanconi anemia group J protein (Fancj), a member of the DEAD/DEAH subfamily of helicase ChlR1, regulator of telomere elongation helicase 1 (RTel1) and DNA replication helicase 2 (Dna2), contain a conserved Fe-S cluster in their N-terminus, which is essential for helicase activities (Wu and Brosh, 2012). RNRs utilize radical chemistry to reduce ribonucleotides to synthesize deoxyribonucleotides (dNTPs), thereby generating the necessary precursors of DNA replication and repair (Zhang, 2014). Imbalanced dNTP pools are associated with increased DNA mutations, DNA strand breaks, and even cell death by enhancing misincorporation of nucleotides and by inhibiting DNA polymerase functions (Kumar et al., 2010; Zhang et al., 2014). The catalytic activity of RNR is dependent on a dincular iron site in the M2 subunit (RRM2) (Aye et al., 2014). Moreover, mammalian cells harbor a p53-inducible RRM2 subunit (p53R2, also known as RRM2B), which is induced in response to DNA damage (Torti and Torti, 2013). Interestingly, p53R2 is sensitive to iron chelation, thus it represents a target for iron chelation therapy in tumours with wild-type p53 (Torti and Torti, 2013).

Cells progress through the cell cycle unchecked may eventually result in malignant tumors (Tenga and Lazar, 2014). Iron is a major regulator of cell cycle by inhibiting either the formation or activities of the cyclin and cyclin-dependent kinase complexes (Zhang, 2014). Intracellular iron disruption by chelators leads to cell cycle arrest, particularly in G1 and S phases (Fu and Richardson, 2007; Sinwardana and Seligman, 2013). In many types of cancers such as sarcomas, colorectal and melanomas, cyclin D overproduction is observed (Burandt et al., 2014; Wang et al., 2014). Cyclin D1 associates with cyclin-dependent kinase 4 (CDK4) and CDK6 to regulate G1/S progression by phosphorylating retinoblastoma tumor suppressor protein (RB), which in turn releases the transcription factor E2F from RB (Torti and Torti, 2013).

Iron and other pathways

Iron is also involved in AKT pathway and VEGF pathway in cancer cells. Iron oxide nanoparticles (Fe2O3 NPs) can mediate cytotoxicity via PI3K/AKT pathway, in which Fe2O3 NPs induce cellular damage and a natural flavonoid quercetin plays a protective role in Fe2O3 NPs induced cytotoxicity and apoptotic death (Sarkar and Sil, 2014). Iron-saturated lactoferrin stimulates cell cycle progression through PI3K/Akt pathway in MCF-7 cells (Lee et al., 2009). Vascular endothelial growth factor (VEGF) is a target of HIF, and its expression is induced in cells exposed to hypoxia (Forsythe et al., 1996). Thus, VEGF pathway is possibly involved in iron-mediated carcinogenesis.

THERAPEUTIC STRATEGIES BASED ON IRON DEPRIVATION

Elevated cellular iron may cause tumorigenesis, therefore decreasing iron level and targeting iron-containing proteins such as RNR have been developed to efficient strategies in chemotherapy. Numerous iron chelators, such as DFO, triapine, deferoxprone, deferasirox and tachpyridine, have been preclinically or clinically used as anticancer agents...
Triapine exhibits wide-spectrum antitumor activity and cytotoxicity (Buss et al., 2003; Yu et al., 2006). Studies suggest that the cytotoxicity of triapine involved multiple mechanisms, such as by forming complexes with both Fe²⁺ and Fe³⁺, and by inhibiting both RRM2 and p53R2 (Enyedy et al., 2011; Zhang et al., 2014). The Fe³⁺-triapine can react with O₂ to produce reactive oxygen species (ROS) (Richardson et al., 2009).

Moreover, some strategies that generate single-chain antibodies targeted towards TfR1 also have been developed (Crepin et al., 2010; Torti and Torti, 2013). TfR1 is mainly targeted in two different ways: (1) delivering therapeutic molecules into malignant cells, and (2) blocking the natural function of the receptor leading directly to cancer cell death (Daniels et al., 2012). Numerous types of anti-cancer drugs targeted TfR1 have been developed, such as a variety of anti-TfR antibodies (HB21, 454A12, B3/25, OKT9, 7D3, 7579 and 42/6) (Daniels et al., 2012), and multiple tumor-targeting ligands which are responsible for the delivery of numerous antitumour cytotoxics (TF-doxorubicin, TF-cisplatin, TF-chlorambucil, TF-ricin A chain and TF-diptheria toxin) (Torti and Torti, 2013). Some studies have obtained promising results for the treatment of a variety of cancers via cytotoxicity induced by the direct inhibition of TfR1 function by its monoclonal antibodies (Daniels et al., 2012). These tumor-targeting ligands can be delivered into cancer cells, causing cytotoxic effects including growth inhibition and/or induction of apoptosis in a variety of malignancies in vitro and in vivo (Daniels et al., 2012).

CONCLUSION
Collectively, altered iron metabolism is a key hallmark of cancer. Iron diversely functions in tumor microenvironment, cancer initiation, progression and metastasis. A variety of signal pathways are activated by iron in cancer cells, and the expression of numerous iron metabolism genes is aberrant in malignant tumors, suggesting the fundamental roles of iron in developing cancer. Although great progresses have been made in the previous studies, the detailed understandings on the mechanisms of iron homeostasis regulation, iron-containing protein functions, and signal transduction involved in iron in cancer cells are still required to further explore.

ACKNOWLEDGMENTS
We apologize to all authors whose contributions were not cited due to space limitations. We would like to express our gratitude to Dr. Jianbin Wang for critically reading the manuscript and for facilitating discussions.

COMPLIANCE WITH ETHICS GUIDELINES
Caiguo Zhang and Fan Zhang declare no conflict of interest.

This article does not contain any studies with human or animal as subjects performed by the authors.

OPEN ACCESS
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

REFERENCES
Al Robaian M, Chiam KY, Blatchford DR, Dufes C (2014) Therapeutic efficacy of intravenously administered transferrin-conjugated dendrplexes on prostate carcinomas. Nanomedicine (Lond) 9:421–434
Aleman MR, Santoloria F, Batista N, de La Vega M, Gonzalez-Reimers E, Milena A, Llanos M, Gomez-Sirvent JL (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19:21–26
Anderson GJ, Vulpe CD (2009) Mammalian iron transport. Cell Mol Life Sci 66:3241–3261
Andrews NC, Schmidt PJ (2007) Iron homeostasis. Annu Rev Physiol 69:69–85
Armaghany T, Wilson JD, Chu Q, Mills G (2012) Genetic alterations in colorectal cancer. Gastrointest Cancer Res 5:19–27
Aye Y, Li M, Long MJ, Weiss RS (2014) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. doi:10.1038/onc.2014.155
Beckman LE, Hagerstrand I, Stenling R, Van Landeghem GF, Beckman L (2000) Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 59:317–322
Berger T, Cheung CC, Elia AJ, Mak TW (2010) Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci USA 107:2995–3000
Bracciolini M (2012) Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 51:53–63
Burandt E, Grunert M, Lebeau A, Choschzick M, Quaas A, Janicke F, Muller V, Scholz U, Bokemeyer C, Petersen C, et al. (2014) Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer. doi:10.1007/s12282-014-0538-y
Buss JL, Torti FM, Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021–1034
Carpagnano GE, Lacedonia D, Palladino GP, Koutelou A, Martinelli D, Orlando S, Foschino-Barbaro MP (2012) Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes? Eur J Clin Investig 42:478–486
Iron homeostasis and cancer

REVIEW

Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 73:200–210

Chen G, Fillebeen C, Wang J, Pantopoulos K (2007) Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis 28:785–791

Chen Y, Zhang Z, Yang K, Du J, Xu Y, Liu S (2014) Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene. doi:10.1038/onc.2014.310

Cheng Z, Dai L, Song YN, Kang Y, Si JM, Xia J, Liu YF (2014) Regulatory effect of iron regulatory protein-2 on iron metabolism in lung cancer. Genet Mol Res 13:5514–5522

Cho H, Kim JH (2009) Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57:513–521

Choi AM, Alam J (1996) Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 15:9–19

Crepin R, Goenaga AL, Jullienne B, Legay C, Benhoud K, Marks JD, Poul MA (2010) Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res 70:5497–5506

Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta D, Holler E, Ljubimova JY, Helguera G, Penichet ML (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291–317

Dayani PN, Bishop MC, Black K, Zeltzer PM (2004) Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 67:367–377

Denic S, Agarwal MM (2007) Nutritional iron deficiency: an evolutionary perspective. Nutrition 23:603–614

Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Farion S, Valentì L (2010) Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 176:1006–1017

Duarte DC, Nicolau A, Teixeira JA, Rodrigues LR (2011) The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 94:66–76

Dunn LL, Suryo Rahmanto Y, Richardson DR (2007) Iron uptake and regulation of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 94:5083

Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J et al (2009) Chelation therapy for brain cancer. J Neurooncol 67:367–377

Eby FR, Bumgarner RW, Goya M, Faux H, Langford ME, Kuijpers T, Liu J, Lucito R, Mavroukakis S, et al. (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol 33:1695–1700

Enyedy EA, Primik MF, Kowol CR, Arion VB, Kiss T, Keppler BK (2011) Interaction of Triapine and related thiosemicarbazones with iron(II)/(III) and gallium(III): a comparative solution equilibrium study. Dalton Trans 40:5895–5905

Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390–5395

Forsey TA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613

Fu D, Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/ WAF1 by iron depletion. Blood 110:752–761

Gkouvatsos K, Papanikolaou G, Pantopoulos K (2012) Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 1820:188–202

Hamalainen P, Saltevo J, Kautiainen H, Mantyselkä P, Vanhala M (2012) Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc Diabetol 11:116

Hewitson KS, McNeill LA, Elkins JM, Schofeld CJ (2003) The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 31:510–515

Hohaus S, Massini G, Giachetì M, Vannata B, Bozzoli V, Cuccaro A, D’Alo F, Larcocca LM, Raymakers RA, Swinkels DW et al (2010) Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 28:2538–2543

Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE (2007) Genetic variability in iron-related oxidative stress pathways (Nrf2, NQO1, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev 16:1784–1794

Hou Y, Zhang S, Wang L, Li J, Qu G, He J, Rong H, Ji H, Liu S (2012) Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene 511:398–403

Iwasaki K, Ray PD, Huang BW, Sakamoto K, Kobayashi T, Tsuji Y (2013) Role of AMP-activated protein kinase in ferritin H gene expression by resveratrol in human T cells. Biochemistry 52:5075–5083

Jakszyn P, Allen NE, Lujan-Barroso L, Gonzalez CA, Key TJ, Fonsesca-Nunes A, Tjonneland A, Fons-Johnsen N, Overvad K, Teucher B et al (2012) Nitrosamines and heme iron and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 21:547–551

Jiang XP, Elliott RL, Head JF (2010) Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 30:759–765

Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA et al (2013) Inhibition of beta2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One 8:e68366

Kalousova M, Krechler T, Jachymova M, Kubena AA, Zák A, Zima T (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol 33:1695–1700

Kaplan CD, Kaplan J (2009) Iron acquisition and transcriptional regulation. Chem Rev 109:4536–4552
Keith B, Johnson RS, Simon MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9–22
Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26:1494–1497
Koreth J, Antin JH (2010) Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica 95:364–366
Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79–86
Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazić M (2010) Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol 27:268–277
Kumar D, Viberg J, Nilsson AK, Chabes A (2010) Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids Res 38:3975–3983
Lee PJ, Jiang BH, Chin BY, Alam J, Semenza GL, Choi AM (2011) Increased hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272:5375–5381
Lee SH, Pyo CW, Hahm DH, Kim J, Choi SY (2009) Iron-saturated lactoferrin stimulates cell cycle progression through PI3K/Akt pathway. Mol Cells 28:37–42
Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Psuszta L, Symmans WF et al (2009) Inhibition of lipocalin 2 impairs breast tumor growth and migration. Cancer Res 69:8579–8584
Leng X, Wu Y, Arlinghaus RB (2011) Relationships of lipocalin 2 with iron metabolism. Biochim Biophys Acta 1823:1491–1498
Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, To C, Panchal D, Tsao MS (2012) Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One 7:e46677
Lill R, Hoffmann B, Molik S, Prierk AJ, Rietzschel N, Stehling OA, Stawski MA, Webert H, Mullenhoff U (2012) The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 1823:1491–1508
Lin X, Yang H, Zhou L, Guo Z (2011) HIF-2α-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 51:97–106
Loc KN, Ponka P (1999) Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274:24147–24152
Lovejoy DB, Richardson DR (2003) Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 10:1035–1049
MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26
MacKenzie EL, Iwasaki K, Tsuji Y (2008) Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 10:997–1030
Maes K, Nemeth E, Roodyman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S et al (2010) In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116:3635–3644
Mannelqvist M, Stefansson IM, Wink E, Kusonmanno K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA (2012) Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 12:169
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Martin JH, Alalami O, Yaqoob F (2000) Differential effects of retinoids on nitric oxide production by promonocytic U937 cells and ZR-75-1 human breast cancer cells. Oncol Rep 7:219–223
Miller JL (2013) Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med 3:a011866. doi:10.1101/cshperspect.a011866
Miyabe I, Kunkel TA, Carr AM (2011) The major roles of DNA polymerases epsilon and delta at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet 7:e1002407
Molina-Montes E, Wark PA, Sanchez MJ, Norat T, Jakobsen P, Lujan-Barroso L, Michaud DS, Crowe F, Allen N, Khaw KT et al (2012) Dietary intake of iron, heme-iron and magnesium and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. Int J Cancer 131:E1134–1147
Moser JC, Rawal M, Wagner BA, Du J, Cullen JJ, Buettner GR (2013) Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Redox Biol 2:22–27
Muckenthaler MU, Galy B, Bentze MW (2008) Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28:197–213
Mukhopadhyay CK, Mazumder B, Fox PL (2000) Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275:21048–21054
Munoz M, Gomez-Ramirez S, Martin-Montanez E, Auerbach M (2014) Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol 20:1972–1985
Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81–89
Ornstein DL, Zacharski LR (2007) Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer 58:115–126
Orrenius S, Nicotera P, Zhivotovsky B (2011) Cell death mechanisms and their implications in toxicology. Toxicol Sci 119:3–19
Osborne NJ, Gurrin LC, Alalami O, Yaqoob F (2000) Differential effects of iron on the transferrin receptor gene. J Biol Chem 274:24147–24152
Park KS, Kim H, Kim NG, Cho SY, Choi KH, Seong JK, Paik YK (2002) Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Biochemistry 51:5705–5724
Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L (2012) Mechanisms of mammalian iron homeostasis. Biochemistry 51:3983–3994
Pausatzkioglu CK, Nemeth E, Fantuzzi G, Llor X, Freels S, Tussing-Humphreys L, Cabaj R, Linzmeier R, Ng D, Clark J et al (2014)
Iron homeostasis and cancer

© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn 99

Review

Protein & Cell

Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond) 11:21

Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, Ford SJ, Stones DH, Iqbal TH, Tselepis C et al (2012) Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep 2:270–282

Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, Bernhardt PV (2009) 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 52:1459–1470

Romero A, Ramos E, de Los Rios C, Egea J, Del Pino J, Reiter RJ (2014) A review of metal-catalyzed molecular damage: protection by melatonin. J Pineal Res 56:343–370

Rossi E (2005) Hecpcin—the iron regulatory hormone. Clin Biochem Rev 26:47–49

Rouault TA (2003) How mammals acquire and distribute iron needed for oxygen-based metabolism. PLoS Biol 1:E79

Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2:406–414

Sakurai K, Sohda T, Ueda S, Tanaka T, Hirano G, Yokoyama K, Morihara D, Aanan A, Takeyama Y, Irie M et al (2014) Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue. Hepatogastroenterology 61:426–430

Sarkar A, Sil PG (2014) Iron oxide nanoparticles mediated cytotoxicity via PI3K/AKT pathway: role of quercetin. Food Chem Toxicol 71:106–115

Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X et al (2014) Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep 7:180–193

Shiba M, Saito K, Fushimi K, Ishigami T, Shinozuka K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A, Sakamoto Y et al (2013) Lipocalin-2 is associated with radioreistance in oral cancer and lung cancer cells. Int J Oncol 42:1197–1204

Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP (2011) Role of ferritin as the iron regulatory hormone. Clin Biochem 44:186–193

Stockert R (1990) Induction of haem oxygenase as a defence against oxidative stress. Free Radical Res Commun 9:101–112

Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274:24412–24416

Tammariello AE, Milner JA (2010) Mouse models for unraveling the importance of diet in colon cancer prevention. J Nutr Biochem 21:77–88

Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM (2009) Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood) 234:693–702

Tenga MJ, Lazar IM (2014) Proteomic study reveals a functional network of cancer markers in the G1-Stage of the breast cancer cell cycle. BMC Cancer 14:710

Thomas C, Mackey MM, Diaz AA, Cox DP (2009) Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep 14:102–108

Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer 13:342–355

Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10:1343–1374

Tsui KH, Chung LC, Wang SW, Feng TH, Chang PL, Juang HH (2013) Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol 51:131–141

Vakkala M, Paakko P, Soini Y (2000) eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 17:667–671

Valerio LG (2007) Mammalian iron metabolism. Toxicol Mech. Methods 17:497–517

Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffman RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095–6099

von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA (2012) Wnt signaling in myogenesis. Trends Cell Biol 22:602–609

Wang J, Pantopoulos K (2002) Conditional derepression of ferritin synthesis in cells expressing a constitutive IRP1 mutant. Mol Cell Biol 22:4638–4651

Wang J, Li Q, Ou Y, Han Z, Li K, Wang P, Zhou S (2011) Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 34:987–995

Wang N, Wei H, Yin D, Lu Y, Zhang Y, Jiang D, Jiang Y, Zhang S (2014) Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo. Int J Clin Exp Pathol 7:4016–4023

Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM (2003) Iron status in mice carrying a targeted disruption of lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 34:987–995

Wei H, Yin D, Lu Y, Zhang Y, Jiang D, Jiang Y, Zhang S (2014) Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo. Int J Clin Exp Pathol 7:4016–4023

Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM (2003) Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 23:178–185

Wu Y, Brosh RM Jr (2012) DNA helicase and helicase-nuclease enzymes with a conserved iron-sulfur cluster. Nucleic Acids Res 40:4247–4260

Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cycling of stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys 346:180–186

Xiong W, Wang L, Yu F (2014) Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol 31:28

Xue X, Shah YM (2013) Intestinal iron homeostasis and colon tumorigenesis. Nutrients 5:2333–2351

Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ, Shah YM (2012) Hypoxia-
inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res 72:2285–2293
Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 106:3913–3918
Yang J, McNeish B, Butterfield C, Moses MA (2013) Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 27:45–50
Yildirim A, Meral M, Kaynar H, Polat H, Ucar EY (2007) Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit 13: CR195–200
Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883
Zhang C (2014) Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 5:750–760
Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM (2008) Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 283:33911–33918
Zhang F, Tao Y, Zhang Z, Guo X, An P, Shen, Y, Wu Q, Yu Y, Wang F (2012) Metalloreductase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses. Haematologica 97:1826–1835
Zhao N, Gao J, Enns CA, Knutson MD (2010) ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem 285:32141–32150